quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:00:00·16d
PRRelease
AtaiBeckley Inc. logo

AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

ATAI· AtaiBeckley Inc.
Health Care
Original source

Companies

  • ATAI
    AtaiBeckley Inc.
    Health Care

Recent analyst ratings

  • Mar 27UpdateDeutsche Bank$12.00
  • Jan 20UpdateGuggenheim$11.00
  • Oct 13UpdateNeedham$12.00
  • Jul 29UpdateOppenheimer$14.00
  • Apr 4UpdateBerenberg-
  • Nov 18UpdateH.C. Wainwright$10.00

Related

  • INSIDER1d
    SEC Form 4 filed by Craig Kevin James
  • SEC1d
    SEC Form DEFA14A filed by AtaiBeckley Inc.
  • SEC1d
    SEC Form DEF 14A filed by AtaiBeckley Inc.
  • PR2d
    AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
  • SEC3d
    SEC Form 144 filed by AtaiBeckley Inc.
  • PR10d
    AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
  • ANALYST28d
    Deutsche Bank initiated coverage on AtaiBeckley with a new price target
  • PR31d
    AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022